Mulugeta Kassahun, MD
Urology · Las Vegas, NVNPI 1922044395
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $8,798 and has fallen 87.2% since, to $1,127 in 2025.
Across 61 payments — averaging $211.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Axonics, Inc.$2K
- Boston Scientific$1K
- Procept Biorobotics Corporation$1K
- Urogen Pharma, Inc.$215
- Medtronic$164
- plus $485 from 8 others
What the payments were for
- Travel & lodging$2,37518%
- Food & beverage$3,50127%
- Education$7,00054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,866 |
| Axonics, Inc. | 10 | $1,568 |
| Boston Scientific | 16 | $1,434 |
| Procept Biorobotics Corporation | 8 | $1,145 |
| Urogen Pharma, Inc. | 2 | $215 |
| Medtronic | 1 | $164 |
| Caldera Medical, Inc | 1 | $143 |
| Urovant Sciences Inc | 1 | $125 |
| Astellas Pharma US Inc | 6 | $100 |
| Coloplast | 1 | $48 |
| AbbVie | 1 | $20 |
| 180 Medical, Inc. | 1 | $18 |
| Bard Access Systems, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,694
- Axonics$1,406
- Bulkamid$1,178
- AquaBeam Robotic System$988
- GENERAL FEMALE SUI$404
- LithoVue$364
- INTERSTIM$164
- GENERAL KIDNEY STONE DISEASE$147
- Desara$143
- JELMYTO$139
- GENERAL ERECTILE DYSFUNCTION$134
- GEMTESA$125
- GENERAL PELVIC ORGAN PROLAPSE$118
- GENERAL - THERAPIES$103
How this compares
$12,876 in reported general payments places this provider in the 75th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 82 | $81,039 |
| Tamsulosin Hcl | 869 | $10,559 |
| Finasteride | 610 | $6,323 |
| Estradiol | 53 | $3,442 |
| Tolterodine Tartrate ErTolterodine Tartrate | 45 | $3,160 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 79 | $1,563 |
| Oxybutynin Chloride ErOxybutynin Chloride | 75 | $1,366 |
| NitrofurantoinNitrofurantoin Macrocrystal | 52 | $857 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 310 | $807 |
| Solifenacin Succinate | 17 | $649 |
| Dutasteride | 24 | $565 |
| Bicalutamide | 31 | $537 |
| Celecoxib | 42 | $478 |
| Ciprofloxacin Hcl | 110 | $413 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 68 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $100 | $81,03982 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 63 urology providers in Nevada.
Other urology in Las Vegas
- Vijay GoliLas Vegas$105K
- Joel AbbottLas Vegas$69K
- Victor GrigorievLas Vegas$59K
- Omid LesaniLas Vegas$27K
- Joseph CandelaLas Vegas$24K
- Lawrence NewmanLas Vegas$22K
- Michael VerniLas Vegas$16K
- Jason ZommickLas Vegas$12K
- Ilya GorbachinskyLas Vegas$11K
- Sheldon FreedmanLas Vegas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.